NCT00098436View on ClinicalTrials.gov

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

August 31, 2008

Conditions
Leukemia
Interventions
DRUG

laromustine

DRUG

temozolomide

Trial Locations (4)

27710

Duke Comprehensive Cancer Center, Durham

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

46202

American Health Network - North Illinois Street, Indianapolis

44106-5065

Case Comprehensive Cancer Center, Cleveland

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00098436 - Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | Biotech Hunter | Biotech Hunter